(Reuters) - Just weeks after completing its $3.6 billion purchase of King Pharmaceuticals, Pfizer Inc has recalled an opioid painkiller obtained in the deal and said it could remain unavailable for many months because of formulation problems.
(Reuters) - Just weeks after completing its $3.6 billion purchase of King Pharmaceuticals, Pfizer Inc has recalled an opioid painkiller obtained in the deal and said it could remain unavailable for many months because of formulation problems.
